Capital Analysts LLC
IOVA icon

Capital Analysts LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Capital Analysts LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$59.3K Buy
+4,000
New +$28.6K ﹤0.01% 959

Other funds holding IOVA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Capital Analysts LLC's IOVA Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Iovance Biotherapeutics (IOVA) in Q3 2026: 4,000 shares worth $59.3K. The stake represents ﹤0.01% of the portfolio and ranks #959 among its holdings.

253 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Capital Analysts LLC held 4,000 shares of Iovance Biotherapeutics worth $59.3K as of Q3 2026.
  • Iovance Biotherapeutics was a new Capital Analysts LLC position in Q3 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #959 holding.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.